3ZLN

Crystal structure of BCL-XL in complex with inhibitor (Compound 3)

3ZLN の概要

• エントリーDOI: 10.2210/pdb3zln/pdb
• 関連するPDBエントリー: 3ZK6 3ZLO 3ZLR
• 分子名称: BCL-2-LIKE PROTEIN 1, 6-[(8E)-8-(1,3-benzothiazol-2-ylhydrazinylidene)-6,7-dihydro-5H-naphthalen-2-yl]pyridine-2-carboxylic acid, SULFATE ION, ... (5 entities in total)
• 機能のキーワード: apoptosis, inhibitor
• 由来する生物種: HOMO SAPIENS (HUMAN)
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 21625.80

構造登録者

Czabotar, P.E.,Lessene, G.L.,Smith, B.J.,Colman, P.M. (登録日: 2013-02-04, 公開日: 2013-04-24, 最終更新日: 2023-12-20)

主引用文献

Lessene, G.L.,Czabotar, P.E.,Sleebs, B.E.,Zobel, K.,Lowes, K.L.,Adams, J.M.,Baell, J.B.,Colman, P.M.,Deshayes, K.,Fairbrother, W.J.,Flygare, J.A.,Gibbons, P.,Kersten, W.J.A.,Kulasegaram, S.,Moss, R.M.,Parisot, J.P.,Smith, B.J.,Street, I.P.,Yang, H.,Huang, D.C.S.,Watson, K.G.
Structure-Guided Design of a Selective Bcl-Xl Inhibitor
Nat.Chem.Biol., 9:390-397, 2013

PubMed Abstract: The prosurvival BCL-2 family protein BCL-X(L) is often overexpressed in solid tumors and renders malignant tumor cells resistant to anticancer therapeutics. Enhancing apoptotic responses by inhibiting BCL-X(L) will most likely have widespread utility in cancer treatment and, instead of inhibiting multiple prosurvival BCL-2 family members, a BCL-X(L)-selective inhibitor would be expected to minimize the toxicity to normal tissues. We describe the use of a high-throughput screen to discover a new series of small molecules targeting BCL-X(L) and their structure-guided development by medicinal chemistry. The optimized compound, WEHI-539 (7), has high affinity (subnanomolar) and selectivity for BCL-X(L) and potently kills cells by selectively antagonizing its prosurvival activity. WEHI-539 will be an invaluable tool for distinguishing the roles of BCL-X(L) from those of its prosurvival relatives, both in normal cells and notably in malignant tumor cells, many of which may prove to rely upon BCL-X(L) for their sustained growth.

PubMed: 23603658
DOI: 10.1038/NCHEMBIO.1246

実験手法

X-RAY DIFFRACTION (2.288 Å)